Benefits
Anxiety ratings after a single oral dose
In a small crossover study, healthy adults who had used cannabis took a single 20 mg hemp CBG tincture or placebo on two days a week apart. Across the session they rated their anxiety lower on CBG than on placebo on a simple 0 to 10 scale. The effect was small, a separate state-anxiety questionnaire did not reach significance, and the study did not adjust for multiple comparisons.
Stress ratings in a controlled stress session
The same study put participants through a standardized public speaking and mental arithmetic stress test delivered by video call. CBG was linked to lower stress ratings than placebo at the first measurement, before the stressor, but not during or after it, and the overall difference across the session was not significant. These were single-session, self-reported ratings.
Verbal memory in the same single-dose study
As a secondary measure, people recalled slightly more words on a standard list-learning test after CBG than after placebo. The difference was borderline, and the researchers called it unexpected and in need of repeating. It came from one session at one dose, so it is not an established effect.
What people report using CBG for
In a survey of people who use CBG or its acidic form, the conditions they most often said they manage with it were disturbed sleep, inflammatory and other chronic pain, and anxiety. Most reported their symptoms slightly to much improved at a typical dose of 10 to 12 mg. Surveys record personal opinions and cannot show that CBG caused any change.
Gut inflammation markers in animal studies
In mice with chemically induced colon inflammation, CBG lowered several inflammation markers, reduced nitric oxide output from immune cells and eased oxidative stress in gut-lining cells. These are laboratory and animal findings, and CBG has not been tested for digestive complaints in people.
Appetite and food intake in animal studies
In rats that had already eaten their fill, oral CBG roughly doubled food intake and prompted more frequent meals without obvious movement or coordination problems. This is an animal finding at doses far higher per unit of body weight than people use, and CBG has not been shown to change appetite in human studies.
Mechanism of action
The mother cannabinoid
CBG comes from cannabigerolic acid (CBGA), the precursor the hemp plant converts into the acids that become THC, CBD and CBC. Because the plant uses it up as it matures, harvested cannabis usually contains only small amounts of CBG, which is why it is called a minor cannabinoid.
Acts at several receptors, only weakly at cannabinoid receptors
In laboratory assays CBG binds the CB1 and CB2 cannabinoid receptors only weakly and can block CB1, which fits its lack of a high. It behaves as a potent alpha-2 adrenoceptor agonist and blocks the 5-HT1A serotonin receptor, targets that could in theory influence stress and mood. These are cell and tissue findings.
Anti-inflammatory and antioxidant actions in cells
In immune cells and gut-lining cells, CBG lowered nitric oxide production, reduced pro-inflammatory signaling and eased oxidative stress, and in animal models it helped preserve nerve cells and raised antioxidant defenses. These mechanisms come from laboratory and animal work, not from human outcomes.
Limited brain entry and an active metabolite
In mice, CBG was cleared quickly and entered the brain poorly, while a breakdown product, cyclo-CBG, built up in brain tissue to a much greater degree, which may matter for any central effects. At its peak brain level CBG produced anxiety-like behavior in mice, not calm, through a pathway that did not depend on CB1 receptors.
Clinical trials
Double-blind, placebo-controlled, crossover field trial conducted remotely; each participant took a single 20 mg hemp-derived CBG tincture and placebo on two days a week apart, pre-registered as NCT05257044 and funded by a company that works with CBG (Cuttler et al. 2024, Sci Rep).
34 healthy adults aged 21 or older who were experienced cannabis users.
CBG lowered overall anxiety ratings versus placebo on a visual analog scale (p = 0.034) and lowered stress ratings at the first time point before the stress test (p = 0.032), though the overall stress difference was not significant. Mood did not differ from placebo (p = 0.081). Verbal memory recall was slightly better with CBG (p = 0.050). There were no subjective drug effects and no measured impairment. The authors did not correct for multiple comparisons and used a single low dose.
Online survey of people who use CBG or cannabigerolic acid, asking which conditions they manage with it, their perceived benefit and satisfaction, and their typical dose and timing (Lutz et al. 2026, J Psychoactive Drugs).
239 self-selected CBG or CBGA users.
The conditions people most often reported using CBG or CBGA to manage were disturbed sleep (62%), inflammatory chronic pain (44%), anxiety (33%), episodic pain (29%) and neuropathic chronic pain (28%). Most rated their symptoms as slightly to much improved, used a typical dose of 10 to 12 mg, felt effects within 15 to 60 minutes of oral use and said they lasted 4 to 6 hours. A survey of user opinions cannot establish cause and effect.
Real-world evidence study in which adults with one of three chronic pain conditions were assigned a 12-week supply of one of three oral cannabinoid capsule formulas; one formula contained 5 mg CBG alongside other cannabinoids (Kruger et al. 2026, Clin Ther).
164 adults with fibromyalgia, rheumatoid arthritis, or knee or hip osteoarthritis who completed the study.
Self-reported symptoms improved across most measures in all three formula groups, with effects ranging from small to large and mostly similar across formulas and pain types. The formula containing CBG (with THCa, CBDa and CBC) was linked to reductions in neuropathic pain intensity. Because CBG appeared only inside a multi-cannabinoid blend with no placebo arm, the result cannot be credited to CBG alone.
Laboratory and animal study of CBG in a chemically induced mouse model of colon inflammation, with supporting experiments in immune cells and intestinal cells (Borrelli et al. 2013, Biochem Pharmacol).
Mice with dinitrobenzene sulphonic acid colitis, plus cultured macrophages and intestinal epithelial cells.
CBG reduced markers of colon inflammation, lowered an enzyme that signals tissue damage, increased an antioxidant enzyme and normalized several inflammatory messengers. In immune cells it cut nitric oxide production in a way linked to the CB2 receptor, and it reduced reactive oxygen species in gut-lining cells. Animal and cell evidence only.
Controlled animal feeding study of oral CBG versus placebo in rats that had already eaten, measuring food intake and meal pattern, with a separate test of movement and coordination (Brierley et al. 2016, Psychopharmacology (Berl)).
Male rats; the study was funded in part by pharmaceutical companies.
At the higher doses tested, CBG roughly doubled total food intake and increased the number of meals eaten, and at the top dose shortened the time to start eating, without causing any movement or coordination problems. The sizes and durations of individual meals did not change. This is an animal finding at high doses, not evidence for appetite in people.
Animal study of CBG in two mouse models of a neurodegenerative disease, assessing motor function, nerve-cell survival and inflammatory and antioxidant markers (Valdeolivas et al. 2015, Neurotherapeutics).
Mice given a nerve toxin and genetically modified R6/2 mice.
In toxin-exposed mice CBG improved motor deficits, helped preserve brain cells, reduced inflammatory activation and raised antioxidant defenses. In the genetic model it produced a smaller but significant improvement in a balance task and partly normalized the activity of several disease-related genes. These are animal findings only; CBG has not been tested for brain conditions in people.